Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
or

Celcuity Inc (CELC)

Celcuity Inc (CELC)
9.00 x 1 11.34 x 1
Post-market by (Cboe BZX)
10.24 -0.30 (-2.85%) 03/28/25 [NASDAQ]
9.00 x 1 11.34 x 1
Post-market 10.24 unch (unch) 16:02 ET
Quote Overview for Fri, Mar 28th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
10.06
Day High
10.67
Open 10.49
Previous Close 10.54 10.54
Volume 232,038 232,038
Avg Vol 265,517 265,517
Stochastic %K 52.10% 52.10%
Weighted Alpha -42.61 -42.61
5-Day Change -0.26 (-2.48%) -0.26 (-2.48%)
52-Week Range 8.53 - 22.04 8.53 - 22.04
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 391,350
  • Shares Outstanding, K 37,130
  • Annual Sales, $ 0 K
  • Annual Income, $ -63,780 K
  • EBIT $ -97 M
  • EBITDA $ -96 M
  • 60-Month Beta 0.65
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.58

Options Overview Details

View History
  • Implied Volatility 222.84% ( -3.08%)
  • Historical Volatility 80.11%
  • IV Percentile 98%
  • IV Rank 95.41%
  • IV High 233.00% on 03/19/25
  • IV Low 11.37% on 06/12/24
  • Put/Call Vol Ratio 5.50
  • Today's Volume 13
  • Volume Avg (30-Day) 27
  • Put/Call OI Ratio 0.81
  • Today's Open Interest 974
  • Open Int (30-Day) 1,050

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.72
  • Number of Estimates 4
  • High Estimate -0.65
  • Low Estimate -0.80
  • Prior Year -0.65
  • Growth Rate Est. (year over year) -10.77%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.53 +20.05%
on 03/04/25
Period Open: 9.43
11.17 -8.33%
on 03/25/25
+0.81 (+8.59%)
since 02/28/25
3-Month
8.53 +20.05%
on 03/04/25
Period Open: 13.84
13.85 -26.06%
on 12/30/24
-3.60 (-26.01%)
since 12/27/24
52-Week
8.53 +20.05%
on 03/04/25
Period Open: 21.60
22.04 -53.54%
on 04/01/24
-11.36 (-52.59%)
since 03/28/24

Most Recent Stories

More News
Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2024 Financial Results and Webcast/Conference Call 

CELC : 10.24 (-2.85%)
Oncology Breakthroughs: How Cancer Research Is Advancing in 2025

/CNW/ -- USA News Group News Commentary – Now that World Cancer Day (Feb. 4) has come and gone, the world and the market are looking towards what's being...

ONCY : 0.6000 (-2.31%)
GNTA : 3.97 (-0.25%)
CELC : 10.24 (-2.85%)
NYT : 48.99 (+0.02%)
SLS : 1.1100 (-4.31%)
ONC.TO : 0.85 (-5.56%)
AMGN : 306.95 (+0.39%)
Celcuity to Participate at Upcoming Cowen and Leerink Investor Conferences

CELC : 10.24 (-2.85%)
Celcuity Inc. Reports Encouraging Overall Survival Data for Gedatolisib in Advanced HR+/HER2- Breast Cancer患者

Celcuity announces promising overall survival data for gedatolisib in HR+, HER2- advanced breast cancer at SABCS.Quiver AI SummaryCelcuity Inc. announced new overall survival (OS) data from a Phase 1b...

CELC : 10.24 (-2.85%)
Celcuity Presents Overall Survival Data from Phase 1b Study Evaluating Gedatolisib in Combination with Palbociclib and Endocrine Therapy at the 2024 San Antonio Breast Cancer Symposium

CELC : 10.24 (-2.85%)
Celcuity Inc. Reports Third Quarter Financial Results and Provides Corporate Update

CELC : 10.24 (-2.85%)
Celcuity Inc. To Present at Upcoming Stifel and Jefferies Investor Conferences

CELC : 10.24 (-2.85%)
Celcuity Inc. Schedules Release of Third Quarter 2024 Financial Results and Webcast/Conference Call

CELC : 10.24 (-2.85%)
Top Five Cancer Types Dominate New US Cases as Biotech Sector Eyes $314B Market by 2032

/CNW/ -- According to a "highly troubling" new study, the rising number of cancer cases in young people is being attributed to "accelerated aging." Further...

ONCY : 0.6000 (-2.31%)
CELC : 10.24 (-2.85%)
OLMA : 4.11 (-2.14%)
BIO : 243.00 (-1.68%)
AZN : 73.79 (+1.30%)
ONC.TO : 0.85 (-5.56%)
Biotech's Developments in Race Against Rising Cancer Rates Revealed

USA News Group – According to a “highly troubling” new study, the rising number of cancer cases in young people is being attributed to “accelerated aging.” Further alarm is being spread by the...

ONCY : 0.6000 (-2.31%)
ONC.TO : 0.85 (-5.56%)
CELC : 10.24 (-2.85%)
OLMA : 4.11 (-2.14%)
BIO : 243.00 (-1.68%)
AZN : 73.79 (+1.30%)

Business Summary

Celcuity Inc. is a cellular analysis company. It engaged in discovering new cancer sub-types and commercializing diagnostic tests designed to significantly improve the clinical outcomes of cancer patients treated with targeted therapies. The company's proprietary CELx diagnostic platform uses a patient's...

See More

Key Turning Points

3rd Resistance Point 11.19
2nd Resistance Point 10.93
1st Resistance Point 10.59
Last Price 10.24
1st Support Level 9.98
2nd Support Level 9.72
3rd Support Level 9.37

See More

52-Week High 22.04
Fibonacci 61.8% 16.88
Fibonacci 50% 15.28
Fibonacci 38.2% 13.69
Last Price 10.24
52-Week Low 8.53

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trading Volatility: How to Use IV Rank & Percentile for Smarter Options Strategies